Brinker Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Brinker Capital’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$221K	Buy	+1,981	New	+$172K	0.01%	887

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Brinker Capital's KRTX Position: Q2 2020 in Review

Brinker Capital opened a new position in Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2020: 1,981 shares worth $221K. The stake represents 0.01% of the portfolio and ranks #887 among its holdings.

130 funds tracked by Wall St. Rank hold KRTX as of Q2 2020.

Brinker Capital held 1,981 shares of Karuna Therapeutics, Inc. Common Stock worth $221K as of Q2 2020.
Karuna Therapeutics, Inc. Common Stock was a new Brinker Capital position in Q2 2020.
Karuna Therapeutics, Inc. Common Stock made up 0.01% of Brinker Capital's portfolio in Q2 2020, its #887 holding.
130 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.